SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020

SMi Group 15 - 16 January 2020, London, UK.
SMi are pleased to present the 12th Annual Pre-Filled Syringes and Injectable Drug Devices conference in London. As Europe's leading Pre-Filled Syringes conference, the 2020 event will assess innovations in device engineering and components, enhancement of human factors, and optimizing packaging and containment.

With the rapid expansion of the PFS market, the regulatory environment is more importance than ever. This year's programme will look at the EU MDR, Article 117 as well as insights into the MDR post-market surveillance requirements; providing a holistic review of the Pre-Filled Syringes industry.

This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior Pre-Filled Syringes Engineers, Device Testing Managers, Heads of Late-Stage Pre-Filled Syringes Development, Head of Medical Affairs, Senior Director - Combination Products & Medical Devices, Global Regulatory Affairs, Quality Assurance Manager Combination Products, Senior Pharmaceutical Assessor and many more.

Benefits of attending

  • Learn about the technological innovations that are revolutionizing the injectable drug delivery space through novel device design
  • Debate how can we prepare for the regulatory impact of Brexit and the EU MDR on devices
  • Hear industry experts uncovering the latest advancements optimizing drug biologics to improve PFS delivery
  • Assess industry case studies exploring how to overcome challenges of extractables and leachables

Chairs for 2019

  • James Mellman, Device Manager, Novartis
  • Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT

Featured speakers

  • Abha Raveau-Violette, Device Manager, AstraZeneca
  • Amanda Matthews, Senior Director, Pfizer
  • Anil-Kumar Busimi, Strategy and Innovation, Senior Global Product Manager, SCHOTT
  • Benjamin Werner, Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Cedric Gysel, Healthcare Solutions Manager, Johnson & Johnson
  • Cinzia Rotella, Senior Materials Scientist, Sanofi
  • Clemens Guenther, Director Nonclinical Safety Consumer Care, Bayer
  • Colin Roscoe, Principal Human Factors Scientist, Teva Pharmaceuticals
  • Hiroki Hasegawa, Researcher, Mitsubishi Gas Chemical Company, Inc
  • James Mellman, Device Manager, Novartis A G
  • Kewei Yang, Pharmaceutical Scientist, Roche
  • Khaudeja Bano, Head of Medical Devices, Abbott Molecular Inc
  • Marion Westwood, Pharmaceutical Assessor, Medicines & Healthcare products Regulatory Agency (MHRA)
  • Matthew Nicolas, Investigator, GlaxoSmithKline
  • Nicolas Eon, Senior Global Product Manager, SCHOTT
  • Olaf Lebau, Design Engineer for Medical Devices and Combination Products, Boehringer Ingelheim GmbH
  • Raphael Nudelman, Director of Chemical and Computational Toxicology, Teva Pharmaceuticals
  • Remy Vomscheid, Director, Devices Development & Technologies, IPSEN Pharmsciences
  • Torsten Kneuss, Quality Assurance Manager Combination Products, Bayer Pharma

Plus, pre-conference workshop day will be taking place on 14th January in London:

Workshop A: A Roadmap to Regulation Quality Management Systems and Technical Standards
Workshop B: Testing Requirements of Pre-Filled Syringes led by Horst Koller, CEO, HK Packaging Consulting GmbH
Workshop C: Extractables and Leachables: Considerations for PFS Platforms

For more information and to register, please visit:
http://www.pre-filled-syringes.com/wpnwl

Early-Bird Rates

  • Register by 29th November to save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Theravance Biopharma and Pfizer Inc. enter global …

Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Pfizer Inc. (NYSE: PFE) ("Pfizer") today anno...

Amgen and Allergan submit Biologics License Applic…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) fo...

Researchers identify immune-suppressing target in …

Researchers at The University of Texas MD Anderson Cancer Center have identified a tenacious subset of immune macrophages that thwart treatment of glioblastoma with anti-...

Intermittent fasting: live 'fast,' live longer?

For many people, the New Year is a time to adopt new habits as a renewed commitment to personal health. Newly enthusiastic fitness buffs pack into gyms and grocery stores...

Pharmacies leave customers hanging when it comes t…

Proper disposal of leftover medication, particularly antibiotics and opioids, can help reduce antibiotic resistance, prevent children from being poisoned and stop the mis...

Researchers determine how a specific protein regul…

Immune checkpoints are surface proteins that cancer cells use to evade immune response. These surface proteins are critical for cancer cell growth and drugs targeting the...

Lynparza approved in the US as a 1st-line maintena…

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US f...

Scientists find a new use for already known anti-c…

The world scientific community is waging a difficult and prolonged war on cancer. New research in the field of immunogenic cell death can extend the area of drugs applica...

Farxiga granted FDA Priority Review for patients w…

AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dap...

Lilly opens Phase 3 clinical trial in RET-mutant m…

Eli Lilly and Company (NYSE: LLY) announced the opening of the LIBRETTO-531 clinical trial [NCT04211337] for selpercatinib, also known as LOXO-292, for treatment-naive RE...

Bristol-Myers Squibb completes divestment of manuf…

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its previously announced divestment of its oral solid, biologics, and sterile product manufa...

FDA approves new treatment option for patients wit…

Today, the U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable (unab...